tigeliflozin

Tigeliflozin is an orally active, small molecule sodium-glucose cotransporter 2 (SGLT2) inhibitor developed by the Tianjin Institute of Pharmaceutical Research for the treatment of type 2 diabetes mellitus. By selectively inhibiting SGLT2 in the proximal convoluted tubules of the kidney, tigeliflozin reduces the reabsorption of filtered glucose and lowers the renal threshold for glucose. This mechanism promotes urinary glucose excretion (glucosuria) and reduces plasma glucose levels in an insulin-independent manner, which also provides secondary benefits such as modest weight loss and blood pressure reduction. It has been investigated in clinical trials in China to evaluate its safety, tolerability, and pharmacokinetic profile.

Other names

tigeliflozin L-proline